1. What is the decision or change (e.g. clinical topic, practice guideline, system design, delivery of care) you are facing or struggling with where a summary of the evidence would be helpful?
We propose an evidence summary of the risks and benefits of white blood cell growth factors (also known as colony-stimulating factors, or CSFs) in people with cancer.
In adults and children with a solid tumor or hematologic malignancy.
- What are the risks and benefits of using a CSF for primary prophylaxis of neutropenic complications?
- What are the risks and benefits of using a CSF for secondary prophylaxis of neutropenic complications?
- What are the risks and benefits of using a CSF to treat neutropenia?
- What are the risks and benefits of CSFs as adjuncts to hematopoietic stem cell transplantation?
Interventions of interest: granulocyte CSFs (G-CSFs) or granulocyte-macrophage CSFs (GM-CSFs), including biosimilars.
Outcomes of interest: febrile neutropenia, infection-related outcomes, hospitalization, survival, chemotherapy dose intensity, stem cell mobilization and transplant outcomes, adverse events.
2. Why are you struggling with this issue?
The evidence in this area continues to evolve, and it's important to incorporate recent evidence into clinical practice guidelines.
3. What do you want to see changed? How will you know that your issue is improving or has been addressed?
We would like to update ASCO's 2015 guideline on this topic.
4. When do you need the evidence report?
Fri, 09/01/2023
5. What will you do with the evidence report?
We would use it as the evidence base for an updated clinical practice guideline.
Optional Information About You
What is your role or perspective? Guideline specialist at professional society
If you are you making a suggestion on behalf of an organization, please state the name of the organization? American Society of Clinical Oncology
May we contact you if we have questions about your nomination? Yes
